203 related articles for article (PubMed ID: 15776867)
1. [Low galectin-3 capacity to discriminate thyroid lesions].
De-León-Mazariegos R; Canedo-Patzi M; Pérez-Enríquez B; Candanedo-Gonzalez F; Saqui-Salces M; Gamboa-Domínguez A; Rull-Rodrigo JA
Rev Invest Clin; 2004; 56(5):623-8. PubMed ID: 15776867
[TBL] [Abstract][Full Text] [Related]
2. Galectin-3 does not reliably distinguish benign from malignant thyroid neoplasms.
Mehrotra P; Okpokam A; Bouhaidar R; Johnson SJ; Wilson JA; Davies BR; Lennard TW
Histopathology; 2004 Nov; 45(5):493-500. PubMed ID: 15500653
[TBL] [Abstract][Full Text] [Related]
3. Expression of cytokeratin 19, HBME-1 and galectin-3 in neoplastic and nonneoplastic thyroid lesions.
Mataraci EA; Ozgüven BY; Kabukçuoglu F
Pol J Pathol; 2012 Mar; 63(1):58-64. PubMed ID: 22535608
[TBL] [Abstract][Full Text] [Related]
4. Diagnostic value of galectin-3 as a marker for malignancy in follicular patterned thyroid lesions.
Oestreicher-Kedem Y; Halpern M; Roizman P; Hardy B; Sulkes J; Feinmesser R; Stern Y
Head Neck; 2004 Nov; 26(11):960-6. PubMed ID: 15386597
[TBL] [Abstract][Full Text] [Related]
5. Galectin-3 and CD44v6 as markers for preoperative diagnosis of thyroid cancer by RT-PCR.
Samija I; Mateša N; Lukač J; Kusić Z
Diagn Mol Pathol; 2011 Dec; 20(4):233-41. PubMed ID: 22089351
[TBL] [Abstract][Full Text] [Related]
6. Usefulness of HBME-1, cytokeratin 19 and galectin-3 immunostaining in the diagnosis of thyroid malignancy.
de Matos PS; Ferreira AP; de Oliveira Facuri F; Assumpção LV; Metze K; Ward LS
Histopathology; 2005 Oct; 47(4):391-401. PubMed ID: 16178894
[TBL] [Abstract][Full Text] [Related]
7. Expression of Galectin-3 and Galectin-7 in thyroid malignancy as potential diagnostic indicators.
Than TH; Swethadri GK; Wong J; Ahmad T; Jamil D; Maganlal RK; Hamdi MM; Abdullah MS
Singapore Med J; 2008 Apr; 49(4):333-8. PubMed ID: 18418527
[TBL] [Abstract][Full Text] [Related]
8. Usefulness of galectin-3 immunohistochemistry in differential diagnosis between thyroid follicular carcinoma and follicular adenoma.
Jakubiak-Wielganowicz M; Kubiak R; Sygut J; Pomorski L; Kordek R
Pol J Pathol; 2003; 54(2):111-5. PubMed ID: 14575419
[TBL] [Abstract][Full Text] [Related]
9. Utility of galectin 3 expression in thyroid aspirates as a diagnostic marker in differentiating benign from malignant thyroid neoplasms.
Aron M; Kapila K; Verma K
Indian J Pathol Microbiol; 2006 Jul; 49(3):376-80. PubMed ID: 17001889
[TBL] [Abstract][Full Text] [Related]
10. Immunohistochemical distinction of follicular thyroid adenomas and follicular carcinomas.
Bryson PC; Shores CG; Hart C; Thorne L; Patel MR; Richey L; Farag A; Zanation AM
Arch Otolaryngol Head Neck Surg; 2008 Jun; 134(6):581-6. PubMed ID: 18559722
[TBL] [Abstract][Full Text] [Related]
11. Galectin-3 and laminin expression in neoplastic and non-neoplastic thyroid tissue.
Fernández PL; Merino MJ; Gómez M; Campo E; Medina T; Castronovo V; Sanjuán X; Cardesa A; Liu FT; Sobel ME
J Pathol; 1997 Jan; 181(1):80-6. PubMed ID: 9072007
[TBL] [Abstract][Full Text] [Related]
12. [Expression and clinical significance of galectin-3 in well-differentiated thyroid carcinoma].
Ouyang D; Chen FJ; Wei MW; Yang AK; Chen ZQ; Li QL; Chen YF
Ai Zheng; 2005 Nov; 24(11):1367-71. PubMed ID: 16552965
[TBL] [Abstract][Full Text] [Related]
13. Galectin-3 is not useful in thyroid FNA.
Mills LJ; Poller DN; Yiangou C
Cytopathology; 2005 Jun; 16(3):132-8. PubMed ID: 15924608
[TBL] [Abstract][Full Text] [Related]
14. Differential expression of galectin-1 and galectin-3 in thyroid tumors. Potential diagnostic implications.
Xu XC; el-Naggar AK; Lotan R
Am J Pathol; 1995 Sep; 147(3):815-22. PubMed ID: 7677193
[TBL] [Abstract][Full Text] [Related]
15. Diagnostic utility of CD56 immunohistochemistry in papillary carcinoma of the thyroid.
El Demellawy D; Nasr AL; Babay S; Alowami S
Pathol Res Pract; 2009; 205(5):303-9. PubMed ID: 19153015
[TBL] [Abstract][Full Text] [Related]
16. Immunohistochemical localization of galectin-3 in malignant and benign human thyroid tissue.
Cvejic D; Savin S; Paunovic I; Tatic S; Havelka M; Sinadinovic J
Anticancer Res; 1998; 18(4A):2637-41. PubMed ID: 9703921
[TBL] [Abstract][Full Text] [Related]
17. [Detection of cytokeratin 19 and thyroperoxidase expressions in the diagnosis of thyroid diseases].
Yang QX; Shao CK; Feng ZY; Huang BQ; Han AJ; Xiong M; Zhao WL; Wu TT
Di Yi Jun Yi Da Xue Xue Bao; 2005 Jun; 25(6):678-81. PubMed ID: 15958307
[TBL] [Abstract][Full Text] [Related]
18. Immunostaining of galectin-3 and CD44v6 using fine-needle aspiration for distinguishing follicular carcinoma from adenoma.
Maruta J; Hashimoto H; Yamashita H; Yamashita H; Noguchi S
Diagn Cytopathol; 2004 Dec; 31(6):392-6. PubMed ID: 15540177
[TBL] [Abstract][Full Text] [Related]
19. Galectin-3 is highly expressed in nonencapsulated papillary thyroid carcinoma but weakly expressed in encapsulated type; comparison with Hector Battifora mesothelial cell 1 immunoreactivity.
Torregrossa L; Faviana P; Camacci T; Materazzi G; Berti P; Minuto M; Elisei R; Vitti P; Miccoli P; Basolo F
Hum Pathol; 2007 Oct; 38(10):1482-8. PubMed ID: 17597183
[TBL] [Abstract][Full Text] [Related]
20. Combined immunohistochemistry for thyroid peroxidase, galectin-3, CK19 and HBME-1 in differential diagnosis of thyroid tumors.
Paunovic I; Isic T; Havelka M; Tatic S; Cvejic D; Savin S
APMIS; 2012 May; 120(5):368-79. PubMed ID: 22515291
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
